Leelyn Smith’s iShares Biotechnology ETF IBB Stock Holding History

Leelyn Smith’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8	Closed	-$1K	–	378
2021 Q4	$1K	Buy	+8	New	+$1.24K	﹤0.01%	369
2021 Q2	–	Sell	-105	Closed	-$16K	–	362
2021 Q1	$16K	Hold	105	–	–	﹤0.01%	258
2020 Q4	$16K	Hold	105	–	–	0.01%	243
2020 Q3	$14K	Hold	105	–	–	﹤0.01%	243
2020 Q2	$15K	Buy	+105	New	+$13.4K	0.01%	285

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Leelyn Smith's IBB Position: Q1 2022 in Review

Leelyn Smith sold out of iShares Biotechnology ETF (IBB) in Q1 2022, closing a stake of 8 shares — an estimated $1K sold.

Leelyn Smith first reported a position in IBB in Q2 2020 and held it in 5 quarters. The position peaked at $16K in Q1 2021. 897 funds tracked by Wall St. Rank hold IBB as of Q1 2022.

Leelyn Smith reported no remaining iShares Biotechnology ETF position as of Q1 2022 after selling out during the quarter.
Leelyn Smith sold 8 iShares Biotechnology ETF shares in Q1 2022, an estimated $1K.
Leelyn Smith first reported a position in iShares Biotechnology ETF in Q2 2020 and held it in 5 quarters.
Leelyn Smith's iShares Biotechnology ETF position peaked at $16K in Q1 2021.
897 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2022.

Based on Leelyn Smith's 13F filing for Q1 2022, filed 11 May 2022.